Hypothesis

Chronic JAK‑STAT activation in aged tissues stems from exhausted SOCS1‑mediated negative feedback, not from irreversible senescent cell damage. Restoring SOCS1 expression or activity will reestablish timely signal termination, preserving the beneficial SASP‑driven coordination of regeneration while preventing maladaptive ISG hyperactivation.

Mechanistic Rationale

• In aged muscle, senescent‑derived IL‑6 drives persistent pJAK2/pSTAT3 in satellite cells, impairing proliferation (1).
• Type III interferon induces SOCS1 more slowly than type I, prolonging JAK‑STAT signaling when negative feedback is weakened (2).
• When SOCS1 fails, unphosphorylated ISGF3 maintains ISG expression, indicating a compensatory response to broken feedback rather than a normal regulatory state (3).
• The SASP also supplies temporally restricted cues that recruit progenitors, limit fibrosis, and aid tumor surveillance (4, 5).
• Fibrotic diseases show correlated pJAK2/pSTAT3 elevation with tissue dysfunction, reversible by JAK inhibition (6).

Thus, the pathology is a failure of the “off switch” (SOCS1), not the presence of the signal itself. Senolytics remove the signal source but also discard the SASP's beneficial timing mechanisms.

Novel Mechanistic Insight

We propose that a small‑molecule epigenetic modulator (e.g., a BET inhibitor) can enhance SOCS1 transcription by opening chromatin at its promoter, thereby restoring the kinetic balance between IFN‑induced SOCS1 synthesis and cytokine‑driven JAK‑STAT activation. This approach would:

1. Allow transient, physiologic SASP peaks to activate JAK‑STAT for regeneration.
2. Accelerate SOCS1‑mediated shutdown, preventing sustained pSTAT3 and downstream ISG accumulation.
3. Preserve non‑canonical ISGF3 functions that rely on pulsatile, not chronic, signaling.

Testable Predictions

1. In aged mouse muscle, treatment with the SOCS1‑inducing compound will increase SOCS1 protein levels within 6 h after IL‑6 exposure, measured by western blot.
2. pSTAT3 phosphorylation kinetics will show a faster return to baseline (half‑life < 30 min) compared with untreated aged controls.
3. Satellite‑cell proliferation (EdU incorporation) will improve to levels seen in young mice, without a reduction in senescent‑cell SA‑β‑gal positivity.
4. Tissue‑level outcomes (force generation, fibrosis histology) will improve, while SASP factors implicated in wound healing (e.g., CXCL12, VEGF) remain detectable at transient peaks.
5. In a fibrosis model (bleomycin‑induced lung), the compound will reduce collagen deposition comparable to tofacitinib but will not decrease senescent‑cell burden, demonstrating dissociation of signaling correction from cell clearance.

Experimental Design

• Animals: 24‑month‑old C57BL/6 mice; young (3‑month) controls.
• Groups: vehicle, SOCS1‑inducer low dose, SOCS1‑inducer high dose, tofacitinib (positive control), senolytic (dasatinib + quercetin) as reference.
• Treatment: daily oral dosing for 2 weeks.
• Readouts: flow cytometry for pSTAT3 in satellite cells; immunofluorescence for SOCS1; qPCR for ISGs (Mx1, Oas1); SA‑β‑gal staining; histology (Masson’s trichrome for fibrosis); functional grip strength or lung compliance.
• Analysis: ANOVA with post‑hoc Tukey; significance set at p<0.05.

If SOCS1 restoration rescues function without clearing senescent cells, it validates the hypothesis that chronic signaling—due to failed feedback—drives pathology, and that preserving the SASP's chaperone role is therapeutically advantageous.